Physician profile
Benjamin Theodore Wadas
NPI 1992321574
$1,882.13
in general payments reported to CMS, 2019-2025
13 companies · $469 in 2025
The $469 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.53 · 2021: $236 · 2022: $494 · 2023: $176 · 2024: $424 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $450.14 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $405.28 | 2022-2025 | Precision7, Total30, Precision 7 |
| Abbvie INC. | $266.85 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $169.18 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $161.73 | 2021-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $118.29 | 2024-2025 | Xdemvy |
| Coopervision INC. | $115.73 | 2021 | |
| Sight Sciences, INC. | $59.00 | 2020 | |
| Oyster Point Pharma, INC. | $44.44 | 2025 | Ryzumvi, Tyrvaya |
| Glaukos Corporation | $30.29 | 2021 | |
| Biotissue Holdings INC. | $23.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.59 | 2023 | |
| Harrow Eye, LLC | $16.08 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.